A phase 2 study demonstrated promising response rates and overall survival in patients with acute myeloid leukemia who were treated with azacitidine plus nivolumab.
Abeparvovec (Zolgensma) is a one-time infusion that replaces the defective or missing SMN1 gene with a functional copy that can create the SMN protein and prevent the loss of motor neurons in patients with spinal muscular atrophy.
Top news of the day from across the health care landscape.
Technological advances have widened the potential solutions to improve adherence to high-cost specialty drugs.
Top news of the day from across the health care landscape.
It’s our job to spend as much time as it takes to help patients feel comfortable with the medications they are taking.
Top news of the week from Specialty Pharmacy Times.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.